Morningstar

J&J to Launch Late-Stage Trial for SLE Treatment After Meeting Endpoint in Mid-Stage Trial

Provided by Dow Jones

By Connor Hart 




  Johnson & Johnson said it will initiate a Phase 3 trial of its treatment for systemic lupus erythematosus, or SLE, after a recent study of the therapy met its primary endpoint. 



  The company said Tuesday that a statistically significant percentage of patients using the treatment, nipocalimab, saw improvements based on results from the systemic lupus erythematosus responder index, a composite measure used to assess treatment response in patients with SLE during clinical studies. 



  Key secondary and exploratory endpoints were met as well, J&J said, and the therapy's safety and tolerability profile was consistent with previous studies, with no new safety signals identified. 



  J&J said these data represent the first positive results of an investigational FcRn blocker treatment to treat SLE, an autoimmune disease that causes one's own immune system to mistakenly attack various tissues. 





  Write to Connor Hart at connor.hart@wsj.com 





  (END) Dow Jones Newswires



  January 06, 2026 09:24 ET (14:24 GMT)


Copyright (c) 2026 Dow Jones & Company, Inc.
  

					The articles, information, and content displayed on this webpage may
					include materials prepared and provided by third parties. Such
					third-party content is offered for informational purposes only and
					is not endorsed, reviewed, or verified by Morningstar.
				
 

					Morningstar makes no representations or warranties regarding the
					accuracy, completeness, timeliness, or reliability of any third-party
					content displayed on this site. The views and opinions expressed in
					third-party content are those of the respective authors and do not
					necessarily reflect the views of Morningstar, its affiliates, or employees.
				
 

					Morningstar is not responsible for any errors, omissions, or delays
					in this content, nor for any actions taken in reliance thereon.
					Users are advised to exercise their own judgment and seek independent
					financial advice before making any decisions based on such content.
					The third-party providers of this content are not affiliated with
					Morningstar, and their inclusion on this site does not imply any
					form of partnership, agency, or endorsement.
				
 

				Popular
				
 
  
 
 
 
 
5 Stocks to Buy Trading at Big Discounts
 
Plus, what recent bond market volatility means for investors. 
 
 
David Sekera, CFA and Sarah Hansen 
 
 
 
2 Undervalued Stocks to Buy With Long-Term Growth Ahead
 
Defense spending and booming data center demand could provide powerful tailwinds for these 4-star stocks. 
 
 
David Sekera, CFA, Sarah Hansen, and Jess Bebel 
 
 
 
The Market May Be Too Pessimistic About This 4-Star Dividend Stock
 
Despite a looming patent cliff, a strong drug pipeline and 4.1% yield give investors reasons for optimism. 
 
 
Karen Andersen, CFA 
 
 
 
What 7 Key Market Indicators Are Telling Investors Right Now
 
US equity valuations have retreated from their recent highs, but all 7 major market indicators remain above their long-term averages. 
 
 
Amy C. Arnott, CFA 
 
 
 
Don’t Overlook the Income Side of Fixed Income
 
Amid bond market tumult, elevated yields are contributing to returns and offering investors a nice income stream. 
 
 
Dan Lefkovitz 
 
 
 
 

			Sponsor Center